Discover · The Research Behind It
Effect of a Pharmacist-Led Educational Intervention on Inappropriate Medication Prescriptions in Older Adults: The D-PRESCRIBE Randomized Clinical Trial — Martin et al., JAMA 2018
Last checked
- Free
- Worldwide
- Research paper
- Reading
- Online
Never stop or reduce a prescribed medicine on your own: some medicines cause withdrawal effects or a relapse if they are stopped or cut down too quickly. Use these resources to plan it with your prescriber.
- Published in
- JAMA, 2018
- Evidence
- Moderate
- Cost
- Free.
What is this paper about?
489 Quebec adults aged 65+ on a potentially inappropriate medicine (sedative-hypnotics, glyburide, NSAIDs or older antihistamines) took part; in intervention pharmacies they got a deprescribing brochure and their doctor a pharmacist's advice. At six months 43% had stopped filling it vs 12% with usual care (risk difference 31%, 95% CI 23–38%); sedative-hypnotics 43% vs 9%. No adverse events needed hospital care; 38% of those tapering a sedative reported withdrawal symptoms.
Why is it in the directory?
Backs up the Canadian Deprescribing Network and deprescribing.org in chapter 06, which offer patient deprescribing brochures of the kind tested here; most relevant to older adults on several medicines and to their carers.
Is it free to read?
Cluster randomised trial — 69 community pharmacies, 489 adults aged 65 or over. Moderate evidence. JAMA 2018;320(18):1889–1898. DOI 10.1001/jama.2018.16131. Free full text in PubMed Central (PMC6248132).
About the paper
- Authors
- Martin P, Tamblyn R, Benedetti A, Ahmed S, Tannenbaum C.
- Published in
- JAMA 2018;320(18):1889–1898
- Kind of study
- Cluster randomised trial — 69 community pharmacies, 489 adults aged 65 or over
- Strength of evidence
- Moderate — good studies, but fewer of them or with some limits
- Free to read
- Free to read (PMC; free at jamanetwork.com)
Good to know
- One Canadian province and six months' follow-up; too few people on antihistamines to analyse.
Where it sits in the directory
Listed under “Coming Off Medication Safely — Tapering & Deprescribing” in chapter 17 of the directory, The Research Behind It, with 12 other listings in the same category.
Similar listings
Also in the directory, with why each one is here.
- Deprescribing benzodiazepine receptor agonists: Evidence-based clinical practice guideline — Pottie et al., Can Fam Physician 2018
Also a free research paper available worldwide, also for clinicians, in the same category.
This deprescribing.org guideline recommends offering a slow taper to adults aged 65 or over who take benzodiazepines or Z-drugs for insomnia, whatever the duration of…
- Deprescribing antipsychotics for behavioural and psychological symptoms of dementia and insomnia: Evidence-based clinical practice guideline — Bjerre et al., Can Fam Physician 2018
Also a free research paper available worldwide, also for clinicians, in the same category.
Guideline from the deprescribing.org team, built with GRADE methods, a Cochrane review of antipsychotic withdrawal trials in dementia and a systematic review for…
- Incidence of antidepressant discontinuation symptoms: a systematic review and meta-analysis — Henssler et al., Lancet Psychiatry 2024
Also a free research paper available worldwide, also for clinicians, in the same category.
Pooled 79 studies (21,002 people) in which an antidepressant or placebo was stopped.
- Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adults — NICE 2022
Also a free research paper available worldwide, also for clinicians, in the same category.
NICE's guideline on withdrawing opioids, benzodiazepines, gabapentinoids, Z-drugs and antidepressants.
- Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis — Nong et al., BMJ 2026
Also a free research paper available worldwide, also for clinicians, listed under “Metabolic Therapies” in the same chapter.
At one year, compared with lifestyle change alone, tirzepatide gave the most extra weight loss (14.9%), then cagrilintide-semaglutide (14.8%), oral semaglutide (10.9%)…
- Guidelines for the management of conditions specifically related to stress — WHO 2013
Also a free research paper available worldwide, also for clinicians, listed under “Talking Therapies” in the same chapter.
WHO guidance for non-specialist health workers on stress after trauma, PTSD and bereavement.
This page sums up the listing in Notbroken’s own words, from the provider’s own pages; Notbroken does not run it. A listing is not a recommendation, and Notbroken hasn’t tested the service. The details were last checked against the paper and its listing on 25 October 2026. Page first published 7 November 2026. Services, prices and opening hours change, so check with the provider before you rely on them. General information, not medical, legal or financial advice. How these pages work · Run this service? Ask for a change.